Wegovy Price & Dosing Guide UAE

Who Is Eligible for Wegovy?

Wegovy is a prescription weight loss medication approved for adults who meet specific medical conditions. Eligible patients include those with either obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight related medical problem. These comorbidities include heart disease, high blood pressure, high cholesterol, type 2 diabetes, and obstructive sleep apnoea.

Medical History and Starting Treatment

Before starting treatment with Wegovy, a physician must review the patient’s complete medical history, especially those with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (an endocrine system condition). Patients with known heart disease, a history of heart attack, or risk of major cardiovascular events should discuss heart health with their doctor. Wegovy is contraindicated in patients with a known serious allergic reaction to semaglutide or any of its ingredients.

Special Populations

Wegovy should not be used during pregnancy, and breastfeeding patients should discuss whether semaglutide passes into breast milk. Patients taking other semaglutide containing products (such as Ozempic or Rybelsus) should not use Wegovy simultaneously. The prescribing physician will assess medical conditions including pancreatitis history, kidney disease, and diabetic retinopathy before approving treatment.

What Does Wegovy Cost in the UAE?

At UAE pharmacies, Wegovy’s monthly cost for the maintenance dose (2.4 mg) ranges from AED 1,200 to AED 1,500. Lower titration doses (0.25–1.0 mg) during the first 12 weeks are less expensive, with pens reported around AED 700–800 each. Clinic-administered programmes that include physician consultations, blood work, and follow-up monitoring typically charge AED 1,800–3,000 per month.

Major UAE pharmacy chains carrying Wegovy include BinSina Pharmacy, Life Pharmacy, and myAster. A valid prescription from a licensed physician is required—pharmacies must verify prescriber credentials, appropriate dosage, and patient details before dispensing.

Insurance Coverage and Self Pay

Most UAE insurance plans regulated by DHA (Dubai) and DOH (Abu Dhabi) do not cover Wegovy. Weight-management medications are generally classified as lifestyle drugs and excluded from standard benefits. Patients in the UAE overwhelmingly self pay out of pocket. In the US, the situation is more nuanced: some commercial insurance pay for Wegovy under obesity treatment benefits, especially those with documented weight related medical problems, but many employer plans exclude it.

Savings Offers and NovoCare Pharmacy Support

In the US market, Novo Nordisk offers a savings offer through NovoCare pharmacy support that can provide maximum savings of up to $500 per month on eligible prescriptions. Unfortunately, no comparable savings offer exists for UAE patients. The NovoCare pharmacy programme also provides patient assistance for eligible patients without commercial insurance coverage. UAE residents should check directly with their local pharmacy about any available manufacturer discounts or loyalty programmes.

How UAE Pricing Compares Globally

UAE pricing (AED 1,200–1,500/month, approximately $326–$408) sits below the US list price of approximately $1,349 per month, comparable to Germany (EUR 172–328/month depending on dose), and significantly above UK NHS access where patients pay only a GBP 9.90 prescription charge. Unlike the UK, no subsidised pricing pathway exists in the UAE—every dirham is out of pocket.

The 5-Step Titration Schedule

Wegovy uses a standardised 16-week dose escalation before reaching the maintenance dose. Each titration step lasts exactly 4 weeks. The rationale is straightforward: gradual GLP-1 receptor activation reduces gastrointestinal side effects that would otherwise cause patients to discontinue treatment early.

Patients who cannot tolerate a dose increase may remain at the previous level for an additional 4 weeks before reattempting escalation. If the 2.4 mg maintenance dose is not tolerated, 1.7 mg may be used as the highest tolerable dose—though clinical efficacy is dose-dependent.

STEP Trial Efficacy Data

The STEP (Semaglutide Treatment Effect in People with Obesity) programme is the largest clinical trial programme ever conducted for a weight-management drug. Five pivotal trials enrolled over 4,500 participants across multiple populations and treatment durations.

STEP 1: The Landmark Trial

Published in the New England Journal of Medicine (2021), STEP 1 randomised 1,961 adults with obesity (BMI ≥30 or ≥27 with comorbidities) to semaglutide 2.4 mg or placebo for 68 weeks. The results were definitive:

• Mean weight loss: −14.9% with semaglutide vs −2.4% placebo
• 86.4% achieved ≥5% weight loss (vs 31.5% placebo)
• 69.1% achieved ≥10% weight loss (vs 12.0% placebo)
• 50.5% achieved ≥15% weight loss (vs 4.9% placebo)

Across the STEP Programme

• STEP 2 (type 2 diabetes): −9.6% weight loss—lower than STEP 1, as expected in diabetic populations
• STEP 3 (intensive behavioural therapy): −16.0% weight loss when combined with low-calorie diet
• STEP 4 (continuation vs withdrawal): −17.4% maintained with ongoing treatment; patients who switched to placebo regained weight
• STEP 5 (2-year data): −15.2% sustained at 104 weeks, confirming long-term durability

Across all STEP trials, semaglutide 2.4 mg consistently delivered 14.9–17.4% body weight reduction in non-diabetic populations, with simultaneous improvements in waist circumference, blood pressure, lipid profiles, and C-reactive protein.

Side Effects by Dose Tier

Gastrointestinal adverse events are the primary side effect of Wegovy, and they follow a predictable pattern tied to dose escalation. Across the STEP programme, cumulative rates for semaglutide 2.4 mg versus placebo were:

• Nausea: 43.9% vs 16.1%
• Diarrhoea: 29.7% vs 15.9%
• Vomiting: 24.5% vs 6.3%
• Constipation: 24.2% vs 11.1%

The critical nuance: 99.5% of GI events were non-serious and 98.1% were mild to moderate. The cumulative incidence of first GI adverse events plateaued after week 20, meaning nearly all side effects appear during the titration window and improve with continued treatment. Only 4.1% of semaglutide patients experienced severe GI events.

This is precisely why the 16-week titration exists. Patients who skip dose steps or escalate too rapidly experience significantly higher rates of nausea and vomiting. The gradual approach allows the gastrointestinal system to adapt to GLP-1 receptor activation at each dose level before increasing. For further comparison of GI side effects across GLP-1 drugs, see our side effects comparison.

Other Common Side Effects

Beyond the most common side effects of nausea and diarrhoea, patients taking Wegovy may also experience upset stomach, feeling bloated, stomach flu (gastroenteritis), and slowed gastric motility where the stomach empties more slowly than usual. Upper respiratory symptoms including sore throat, runny nose, and sinus congestion are reported in 5–10% of patients. Some patients report feeling dizzy during the initial titration weeks, particularly when combined with blood sugar fluctuations. Hair loss (telogen effluvium) is a less common side effect associated with rapid weight loss rather than the medication itself. Trouble swallowing has been reported rarely. Patients should seek medical help immediately if they experience severe abdominal pain, signs of an allergic reaction (swelling, difficulty breathing), or persistent vomiting.

Serious Side Effects and Boxed Warnings

Wegovy carries a boxed warning regarding thyroid tumors. In animal studies, semaglutide caused thyroid tumors including medullary thyroid carcinoma in rodents. While the relevance to humans is uncertain, patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (an endocrine system condition) should not take Wegovy. Other serious side effects include pancreatitis, gallbladder problems, low blood sugar (hypoglycaemia, especially those taking insulin or sulfonylureas), kidney injury, and increased heart rate.

Cardiovascular Safety: The SELECT Trial

The SELECT trial demonstrated that Wegovy reduces the risk of major cardiovascular events—including heart attack, stroke, and cardiovascular death—by 20% in adults with known heart disease and either obesity or overweight. This was the first time a weight loss medication demonstrated major adverse cardiovascular events reduction. Heart health benefits were observed regardless of whether patients had type 2 diabetes. The FDA updated Wegovy’s label in March 2024 to include cardiovascular risk reduction as an indication.

Pen Specifications & Storage

In the UAE and Europe, Wegovy is supplied as FlexTouch multi-dose pre filled pens. Each wegovy pen contains 4 weekly doses (one month’s supply). A new disposable needle (NovoFine Plus or NovoTwist) must be attached before each once weekly injection. Each dose strength has a dedicated pre filled pen—patients cannot dial a different dose.

Injection Technique and Sites

Wegovy is administered as a subcutaneous injection into the abdomen, upper arm, or thigh. Patients should rotate injection sites and avoid injecting into the same day’s area repeatedly. The injection should be given on the same day each week, at any time of day, with or without meals. If a dose is missed and the next scheduled dose is more than 2 days away, administer the last dose as soon as possible. Taking Wegovy at higher doses than prescribed is not recommended—patients should follow the titration schedule and never exceed their prescribed weekly dose.

Storage Requirements

• Before first use: Refrigerated at 2–8°C (36–46°F)
• After first use: Room temperature (up to 30°C / 86°F) for a maximum of 28 days
• Keep in original carton to protect from light
• Do not freeze—discard if frozen
• Once removed from refrigeration, the 28-day window cannot be reset by re-refrigerating

Shelf life is 24 months when stored properly under refrigeration. For a broader overview of peptide storage principles, see our stability and storage guide.

Diet and Increased Physical Activity on Wegovy

Wegovy is approved for use alongside a reduced calorie diet and increased physical activity. The STEP trials required all participants to follow a calorie diet and increased exercise programme, making lifestyle modification a core component of the weight loss journey. Patients who combine Wegovy with a structured reduced calorie diet and increased physical activity consistently lose weight more effectively than those relying on medication alone.

Nutritional Guidance

A reduced calorie diet typically targets a 500–750 calorie daily deficit, adjusted based on several factors including starting weight, activity level, and metabolic rate. Because Wegovy slows gastric motility and reduces appetite, patients naturally eat less. However, ensuring adequate protein intake (1.2–1.6 g/kg body weight) is critical to preserve lean muscle mass during the weight loss journey. Patients should prioritise nutrient-dense foods and avoid ultra-processed options that provide empty calories.

Exercise and Blood Sugar Management

Increased physical activity of at least 150 minutes per week of moderate-intensity exercise helps patients lose weight faster, maintain muscle mass, and improve blood sugar control. For patients with type 2 diabetes, monitoring blood sugar is essential—combining Wegovy with insulin or sulfonylureas may increase the risk of low blood sugar (hypoglycaemia). Patients should work with their healthcare provider to adjust diabetes medications when starting treatment with Wegovy. Wegovy reduces appetite and improves glycaemic control, but diet and increased physical activity remain the foundation for lasting results.

Wegovy vs Ozempic: Same Molecule, Different Drug

Wegovy and Ozempic are both semaglutide manufactured by Novo Nordisk. The critical differences are regulatory indication, dosing ceiling, and titration protocol.

• Indication: Wegovy is approved specifically for chronic weight management. Ozempic is approved for type 2 diabetes and cardiovascular risk reduction. Many patients use Ozempic off-label for weight loss.
• Maximum dose: Wegovy reaches 2.4 mg/week through 5 titration steps. Ozempic caps at 2.0 mg/week (most patients settle at 1.0 mg).
• Titration: Wegovy’s 5-step protocol takes 16 weeks. Ozempic has a simpler 3-step escalation (0.25 → 0.5 → 1.0 mg, with optional 2.0 mg).
• Pen format: Both use FlexTouch pens in the UAE, but Wegovy pens are dose-specific while Ozempic pens allow multi-dose dialling.

In May 2024, Novo Nordisk publicly urged UAE patients using Ozempic for weight loss to switch to Wegovy—the properly indicated product—to free up Ozempic supply for diabetic patients who depend on it. The higher semaglutide dose in Wegovy (2.4 mg vs 1.0–2.0 mg) also translates to incrementally greater weight loss. For a detailed comparison of liraglutide versus semaglutide, see our Saxenda vs Ozempic analysis.

The Wegovy Pill: Oral Semaglutide for Weight Loss

In December 2025, the FDA approved the oral wegovy pill—the first oral semaglutide formulation specifically indicated for weight loss. The wegovy pill eliminates the need for subcutaneous injection, making the weight loss journey more accessible for patients who prefer oral medication over a once weekly injection. The oral formulation uses the same active ingredient (semaglutide) but with an absorption enhancer (SNAC) that protects the peptide from stomach acid.

The wegovy pill demonstrated comparable weight loss to injectable Wegovy in clinical trials, with the convenience of daily oral dosing. However, the wegovy pill requires strict administration: patients must take it on an empty stomach with no more than 4 oz of plain water, then wait at least 30 minutes before eating, drinking, or taking other medications. The oral version is not yet available in the UAE—patients currently use the injectable pre filled pen. For a broader overview of emerging oral obesity drugs, see our oral obesity drug pipeline analysis.

How Does Retatrutide Compare?

Retatrutide is an investigational triple-receptor agonist (GLP-1, GIP, and glucagon) that has demonstrated substantially greater weight loss than Wegovy in clinical trials.

• Phase 2 (NEJM 2023): Up to 24.2% weight loss at 48 weeks with the 12 mg dose, versus Wegovy’s 14.9% at 68 weeks
• Phase 3 TRIUMPH-4 (December 2025): 28.7% weight loss at 68 weeks in participants with obesity and knee osteoarthritis, with a 75.8% reduction in WOMAC pain scores

The triple-agonist mechanism works through three complementary pathways: GLP-1 receptor agonist activity suppresses appetite and slows gastric emptying, GIP enhances insulin sensitivity and may amplify fat-tissue effects, and glucagon receptor activation increases energy expenditure and promotes fat oxidation. This multi-pathway approach helps patients lose weight significantly faster than single-agonist medications. Wegovy reduces body weight by approximately 15%, while retatrutide nearly doubles that figure—especially those with severe obesity stand to benefit from the greater efficacy.

Retatrutide is not approved for clinical use anywhere. Seven additional TRIUMPH Phase 3 trials are expected to report through 2026, evaluating efficacy in obesity, type 2 diabetes, sleep apnoea, chronic low back pain, cardiovascular/renal outcomes, and MASLD. For a comprehensive comparison of next-generation obesity compounds, see our retatrutide vs tirzepatide vs CagriSema analysis.